
Bio-Rad Laboratories (BIO) Stock Forecast & Price Target
Bio-Rad Laboratories (BIO) Analyst Ratings
Bulls say
Bio-Rad Laboratories demonstrates a solid financial outlook driven by its diverse revenue streams, with clinical diagnostics accounting for 60% of sales and life sciences contributing 40%, securing a strong position in both markets. The company is expected to benefit from ongoing ERP efficiencies, which are anticipated to enhance margins and improve operational effectiveness. Furthermore, analysts foresee a reversal of current pressures as macroeconomic conditions stabilize, alongside the expectation of continued strategic execution towards FY’25 targets, which could positively impact overall financial multiples.
Bears say
Bio-Rad Laboratories has issued new revenue guidance indicating a projected decline of approximately $40 million, or 40%, in sales to federally funded academic and government customers, which is markedly more conservative compared to peers like Thermo Fisher Scientific and Avantor. The company has also lowered its full-year top-line revenue and margin expectations by about 200 basis points each, despite achieving a beat in Q1 2025. Additionally, there are concerns regarding a potential demand slowdown influenced by macroeconomic conditions, which have not been adequately addressed by management compared to its competitors.
This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.
Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction
Start investing in Bio-Rad Laboratories (BIO)
Order type
Buy in
Order amount
Est. shares
0 shares